Avectas

Main focus: Next-generation delivery technology for gene editing

Company stage: Pre-clinical

Diseases: Cancer

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Dublin, Ireland

Website: https://avectas.com/

Partners: ONK Therapeutics

Avectas develops its proprietary SOLUPORE® technology to genetically engineer T cells and natural killer (NK) cells to enable the next generation of gene-modified cell therapies. The company has established a collaboration with ONK Therapeutics, however, it yet has to disclose any proprietary or partnered therapeutic programmes.

Avectas

Your Latest CMN News

CRISPR Unlocks Sweeter Tomatoes Without Yield Loss

Carbon

Nov. 19, 2024

Chinese scientists have achieved a significant advance in tomato agriculture by leveraging CRISPR–Cas9 to enhance sweetness without yield loss. The...

Tackling Antibiotic-Resistant Staphylococcus...

CMN Interview

Nov. 18, 2024

Researchers in Japan have used phagemids for the delivery of CRISPR components to bacteriophage, selectively killing multi-drug resistant bacteria in...

CMN Weekly (15 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 15, 2024

Some of the best links we picked up around the internet

CRISPR Screens Identify Vital lncRNAs

CMN Briefs

Nov. 12, 2024

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...

CMN Weekly (8 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 8, 2024

Some of the best links we picked up around the internet

Researchers Report Fewer Large DNA Deletions After...

CMN Briefs

Nov. 7, 2024

Researchers in Korea report that large DNA deletions occur during DNA repair at a much lower frequency for base editors and prime editors than for...